Docetaxel in Treating Children With Recurrent Solid Tumors
|ClinicalTrials.gov Identifier: NCT00002825|
Recruitment Status : Completed
First Posted : March 1, 2004
Last Update Posted : February 5, 2013
|Condition or disease||Intervention/treatment||Phase|
|Brain and Central Nervous System Tumors Neuroblastoma Sarcoma||Biological: filgrastim Drug: docetaxel||Phase 2|
I. Determine the response rate to docetaxel in children with recurrent sarcomas, neuroblastomas, or brain tumors.
II. Describe the toxic effects of docetaxel in these patients.
All patients receive docetaxel with G-CSF every 21 days for up to 12 courses. Patients are followed for survival.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A PHASE II STUDY OF DOCETAXEL (TAXOTERE) (NSC# 628503) IN CHILDREN WITH RECURRENT SOLID TUMORS|
|Study Start Date :||January 1997|
|Primary Completion Date :||December 2004|
Experimental: Arm I
All patients receive docetaxel with G-CSF every 21 days for up to 12 courses.
|Biological: filgrastim Drug: docetaxel|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002825
Show 36 Study Locations
|Study Chair:||Theodore Zwerdling, MD||University of California, Davis|